Gene expression profiling of diffuse large B-cell lymphoma supervised by CD21 expression.

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous non-Hodgkin lymphoma.
• CD21 expression is recognized as a prognostic indicator in DLBCL.
• Understanding the molecular basis of CD21 expression is crucial for improving patient outcomes.

Purpose of the Study:

• To investigate the gene expression profiles of DLBCL cases based on CD21 expression.
• To identify molecular signatures associated with CD21 status and their prognostic implications.
• To correlate CD21 expression with DLBCL subtypes and patient survival.

Main Methods:

• Gene expression profiling of 40 DLBCL cases stratified by CD21 expression.
• Analysis of signature genes using Gene Ontology Tree Machine.
• Hierarchical cluster analysis of published gene expression datasets.
• Immunohistochemical analysis of surface IgM (sIgM) in 216 DLBCL cases.

Main Results:

• Genes related to the immune system were significantly upregulated in CD21-negative DLBCLs.
• CD21-positive DLBCLs, especially germinal center B-cell-like (GCB) subtypes, demonstrated significantly better overall survival compared to CD21-negative cases.
• CD21 expression status successfully stratified patients into distinct prognostic groups in independent datasets.
• IGHM was identified as a top classifier gene for CD21 expression, and IGHM-related categories were significant in CD21-negative DLBCLs.
• Surface IgM-positive DLBCLs showed significantly poorer overall survival than surface IgM-negative DLBCLs.

Conclusions:

• CD21 expression is a significant prognostic marker in DLBCL, particularly in non-GCB subtypes.
• Distinct molecular profiles, including immune system gene upregulation, characterize CD21-negative DLBCL.
• Surface IgM expression serves as a potential surrogate marker for poor prognosis in DLBCL, aligning with CD21 expression patterns.